Caris Life Sciences, Inc. SEC filings CAI
Caris Life Sciences, Inc. has 134 filings in SEC EDGAR's recent list, going back to Jun 10, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| CERT | Nyse texas certification | Jun 16, 2026 | — |
| 8-A12B | Form 8-a12b | Jun 16, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Apr 2, 2026 | Apr 1, 2026 |
| 10-K | Annual report | Mar 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 30, 2025 | Oct 30, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jun 20, 2025 | Jun 20, 2025 |
| 424B4 | Prospectus | Jun 20, 2025 | — |
| S-8 | Employee stock plan registration | Jun 18, 2025 | — |
| EFFECT | Filing | Jun 17, 2025 | — |
| CERT | Filing | Jun 17, 2025 | — |
| S-1/A | Amended registration statement | Jun 16, 2025 | — |
| 8-A12B | Filing | Jun 13, 2025 | — |
| CORRESP | Letter to the SEC | Jun 13, 2025 | — |
| CORRESP | Letter to the SEC | Jun 13, 2025 | — |
| S-1/A | Amended registration statement | Jun 9, 2025 | — |
| S-1 | Registration statement | May 23, 2025 | — |
| DRS/A | Filing | May 8, 2025 | — |
| DRSLTR | Filing | May 7, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2025 | — |
| DRS/A | Filing | Apr 4, 2025 | — |
| DRSLTR | Filing | Feb 7, 2025 | — |
| DRS/A | Filing | Feb 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2025 | — |
| DRSLTR | Filing | Dec 20, 2024 | — |
| DRS/A | Filing | Dec 20, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| DRSLTR | Filing | Sep 12, 2024 | — |
| DRS/A | Filing | Sep 12, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2024 | — |
| DRS | Filing | Jun 10, 2024 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CAI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Irving, TX
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2019410
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.